5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat and monkey models of L-DOPA-induced dyskinesia. Different mechanisms have been proposed to underlie this effect. Activation of pre-synaptic 5-HT1 receptors has been suggested to inhibit dysregulated release of dopamine from the serotonin terminals, and thus, abnormal activation of striatal dopamine receptors. Activation of post-synaptic 5-HT1 receptors expressed in non-serotonergic neurons in different brain areas, by contrast, has been shown to result in decreased glutamate and GABA release, which may also contribute to the antidyskinetic effect. To unveil the relative contribution of these mechanisms, we have investigated the effect of incre...
After chronic use of l-3,4-dihydroxyphenylalanine (l-DOPA), most Parkinson’s disease (PD) patients s...
Selective activation of 5-HT1 receptors has been shown to produce near to full suppression of l-DOPA...
L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of P...
5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat a...
5-HT(1) receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
n patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost...
In patients with Parkinson’s disease, the therapeutic efficacy of L-DOPAmedication is gradually lost...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually los...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia represents the most problematic side effect during chronic L-DOPA treatment...
The serotonin system has recently emerged as an important player in the appearance of l-DOPA-induced...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
l-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of Parkinson's diseas...
After chronic use of l-3,4-dihydroxyphenylalanine (l-DOPA), most Parkinson’s disease (PD) patients s...
Selective activation of 5-HT1 receptors has been shown to produce near to full suppression of l-DOPA...
L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of P...
5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat a...
5-HT(1) receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
n patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost...
In patients with Parkinson’s disease, the therapeutic efficacy of L-DOPAmedication is gradually lost...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually los...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia represents the most problematic side effect during chronic L-DOPA treatment...
The serotonin system has recently emerged as an important player in the appearance of l-DOPA-induced...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
l-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of Parkinson's diseas...
After chronic use of l-3,4-dihydroxyphenylalanine (l-DOPA), most Parkinson’s disease (PD) patients s...
Selective activation of 5-HT1 receptors has been shown to produce near to full suppression of l-DOPA...
L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) represent the main side effect of P...